Amarin (AMRN) Expected to Announce Quarterly Earnings on Wednesday

Amarin (NASDAQ:AMRN) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($1.27) per share and revenue of $50.6190 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:00 AM ET.

Amarin Stock Down 0.8%

Shares of AMRN opened at $15.59 on Monday. The firm has a market cap of $324.12 million, a price-to-earnings ratio of -6.26 and a beta of 0.84. The business’s 50 day moving average is $14.73 and its two-hundred day moving average is $15.77. Amarin has a 52-week low of $7.08 and a 52-week high of $20.90.

Analysts Set New Price Targets

Several research firms recently issued reports on AMRN. Zacks Research cut shares of Amarin from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amarin in a research report on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of Amarin from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. Three analysts have rated the stock with a Sell rating, According to MarketBeat, Amarin has an average rating of “Strong Sell” and a consensus price target of $12.00.

Institutional Trading of Amarin

Institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in shares of Amarin in the 4th quarter valued at about $239,000. Millennium Management LLC lifted its holdings in Amarin by 25.6% in the fourth quarter. Millennium Management LLC now owns 166,235 shares of the biopharmaceutical company’s stock worth $2,320,000 after acquiring an additional 33,844 shares during the last quarter. Jump Financial LLC lifted its holdings in Amarin by 38.7% in the fourth quarter. Jump Financial LLC now owns 26,900 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 7,500 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Amarin by 34.8% in the fourth quarter. Wells Fargo & Company MN now owns 9,254 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 2,390 shares during the period. Finally, Jane Street Group LLC grew its holdings in shares of Amarin by 90.6% during the fourth quarter. Jane Street Group LLC now owns 32,832 shares of the biopharmaceutical company’s stock valued at $458,000 after purchasing an additional 15,608 shares during the last quarter. 22.25% of the stock is owned by institutional investors and hedge funds.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.